In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $38.00. The company’s shares closed yesterday at $23.05.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Amin is a 2-star analyst with an average return of 0.5% and a 43.75% success rate. Amin covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Sarepta Therapeutics, and Viking Therapeutics.
In addition to Piper Sandler, Centessa Pharmaceuticals also received a Buy from Wells Fargo’s Benjamin Burnett in a report issued on October 1. However, on September 25, BMO Capital assigned a Hold rating to Centessa Pharmaceuticals (NASDAQ: CNTA).
The company has a one-year high of $24.57 and a one-year low of $9.60. Currently, Centessa Pharmaceuticals has an average volume of 1.22M.
Read More on CNTA:
Disclaimer & DisclosureReport an Issue
- Alkermes, Centessa added to Q4 2025 Tactical Ideas List at Wells Fargo
- Centessa Pharmaceuticals: Promising Prospects for ORX750 Justify Buy Rating
- Centessa Pharmaceuticals: Buy Rating Based on Promising Orexin Agonist Program and Market Potential
- Jefferies says stage set for Centessa to differentiate in narcolepsy
- Centessa rises 15.1%
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
